SUMMARY
Alzheimer's disease is one of the most important diseases related to ageing. The social and human
cost is very high especially because of the increase in the normal life span in developed countries.
There is presently no cure for the disease and stimulating the cholinergic central neurotransmission
is today the only therapeutic approach which has been shown to successfully improve the cognitive
state in a significant population of patients. In such a context, research projects should be aimed
specifically at reducing brain lesions resulting from the disease, especially those due to the amyloid
peptide accumulation, and at reducing or even halting the clinical evolution of the disease and
consequent neurodegenerative processes.
KEY WORDS
neuroprotection; amyloid protein precursor (APP); betaA4 protein; tau protein; astrocytes; excitatory amino acids
REFERENCES
Allain H, Bentue-Ferrer D, Trubut O, Gauthier S,
Michel BF, Drieu-La-Rochelle C: Alzheimer's
disease: the pharmacological pathway. Fund
Clin Pharmacol 17:419-428, 2003.
Bains JS, Shaw CA: Neurodegenerative
disorders in humans: the role of glutathione in
oxidative stress-mediated neuronal death. Brain
Res Rev 25:335-358, 1997.
Bush AI: Metal complexing agents as therapies for
Alzheimer's disease. Neurobiol Aging 23:1031-1038, 2002.
Castro A, Martinez A: Inhibition of tau protein
phosphorylation: a new therapeutic strategy for
the treatment of Alzheimer's disease and other
neurodegenerative disorders. Exp Opin Ther
Patents 10:1519-1527, 2000.
Citron M: Emerging Alzheimer's disease therapies:
inhibition of beta-secretase. Neurobiol Aging 23:1017-1022, 2002.
Cutler NR, Sramek JJ: Review of the next
generation of Alzheimer's disease therapeutics: challenges for drug development. Prog. Neuro-Psychopharmacol. Biol Psychiat 25:27-57, 2001.
DeFeudis FV: Gingko biloba extract (Egb 761).
From chemistry to the clinic. Ullstein Medical,
Wiesbaden, pp. 401, 1998.
Doble A: The role of excitotoxicity in
neurodegenerative disease: implications for
therapy. Pharmacol Ther 81:163-221, 1999.
Emilien G, Beyreuther K, Masters C,
Maloteaux JM: Prospects for pharmacological
intervention in Alzheimer's disease. Arch
Neurol 57:454-459, 2000.
Friedlander RM: Mechanism of disease: apoptosis
and caspases in neurodegenerative diseases. N
Engl J Med 348:1365-1375, 2003.
Gandy S: Molecular basis for anti-amyloid therapy
in the prevention and treatment of Alzheimer's
disease. Neurobiol Aging 23:1009-1016, 2002.
Gao WQ, Well RJ, Dugich-Djordjevic M: The
therapeutic potentials of neurotrophic factors for
diseases of the nervous system. Expert Opin
Ther Patents 7:325-338, 1997.
Gasparini F, Lingenhohl K, Stoehr N, Flor PJ,
Heinrich M, Vranesic L, Biollaz M,
Allgeier H, Heckendorn R, Urwyler S,
Varney MA, Johnston EC, Hess SD,
Rao SP, Sacaan AI, Santori EM,
Velicelebi G, Khun R: 2-methyl-6-
(phenylethynyl)-pyridine (MPEP), a potent,
selective and systemically active mGlu5 receptor
antagonist. Neuropharmacology 38:1493-1503, 1999.
Had-Aissouni L, Re DB, Nieoullon A,
Kerkerian-LeGoff L: Importance of astrocytic
inactivation of synaptically released glutamate
for cell survival in the central nervous system -
are astrocytes vulnerable to low intracellular
glutamate concentrations? J Physiol (Paris) 96:317-322, 2002.
Hock C, Konietzko U, Streffer JR: Antibodies
against beta-amyloid slow cognitive decline in
Alzheimer's disease. Neuron 38:547-554, 2003.
Lesh KP: Gene transfert to the brain: emerging
therapeutic strategy in psychiatry? Biol Psych
45:247-253, 2002.
Nieoullon A: Bases cellulaires des processus
degeneratifs. Therapie 53:21-29, 1998.
Re DB, Boucraut J, Samuel D, Birman S,
Kerkerian-LeGoff L, Had-Aissouni L:
Glutamate transport alteration triggers
differentiation-state selective oxidative death of
cultured astrocytes: a mechanism different from
excitotoxicity depending on intracellular GSH
content. J Neurochem 85:1159-1170, 2003.
Roberts SB: gamma-secretase inhibitors and
Alzheimer's disease. Adv Drug Delivery Rev
54:1579-1588, 2002.
Rothstein JD, Dykes-Hoberg G, Pardo CA,
Bristol LA, Jin L, Kuncl RW, Kanai Y,
Hediger MA, Wang Y, Schielke JP,
Weltry FD: Knock out of glutamate transporters
reveals a major role for astroglial transport in
excitotoxicity and clearance of glutamate.
Neuron 16:675-686, 1996.
Scorer CA: Preclinical and clinical challenges in
the development of disease-modifying therapies
for Alzheimer's disease. Drug Discovery
Today 6:1207-1219, 2001.
Sramek JJ, Cutler NR: Recent developments
in the drug treatment of Alzheimer's disease.
Drug and Aging 14:359-373, 1999.
Xu H, Gouras GK, Greenfield JP: Estrogen
reduces neuronal generation of Alzheimer
beta-amyloid peptides. Nature Med 4:447-451, 1998.
|
CITED
Nieoullon A. Neurodegenerative diseases and neuroprotection: current views and prospects. J Appl Biomed. 9: 173-183, 2011.
Ranganatha SR, Malviya M, Kumar YCS, Vinaya K, Prasanna DS, Subhash MN, Rangappa KS. Effect of novel amino acids and dipeptides substituted
3-morpholino arecoline derivatives as muscarinic receptor 1 agonists in Alzheimer's dementia models. Int J Pept Res Ther. 15: 323-337, 2009.
Kunesova G, Hlavacek J, Patocka J, Evangelou A, Zikos C, Benaki D, Paravatou-Petsotas M, Pelecanou M, Livaniou E, Slaninova J. The multiple T-maze
in vivo testing of the neuroprotective effect of humanin analogues. Peptides. 29: 1982-1987, 2008.
Patocka J, Strunecka A. Insulin and memory. [Inzulin a pamet]. Psychiatrie. 11: 18-20, 2007.
Patocka J, Slaninova J, Kunesova G. Neuroprotective peptides as drug candidates against Alzheimer's disease. J Appl Biomed. 3: 67-73, 2005.
Strunecka A, Patocka J, Sarek M. How does lithium mediate its therapeutic effects? J Appl Biomed. 3: 25-35, 2005.
|
